AI Clinical Tools

Allen & Overy Shearman Sterling published guidance on April 14, 2026, addressing data provenance in AI-driven pharmaceutical R&D—a critical issue as drug developers race to cut costs and accelerate timelines. The firm's Q&A examines why datasets must be traceable, compliant, and legally defensible as biotech AI platforms accumulate vast data pools for therapy identification, protein pattern recognition, and clinical optimization. When major pharmaceutical companies acquire these AI capabilities, rigorous due diligence becomes essential to manage legal exposure, privacy violations, and intellectual property disputes.